학술논문
Five-Year Outcomes with Pembrolizumab Versus Chemotherapy as First-Line Therapy in Patients with Non-Small-Cell Lung Cancer and Programmed Death Ligand-1 Tumor Proportion Score ≥ 1% in the KEYNOTE-042 Study
Document Type
Article
Author
Source
In: Journal of Clinical Oncology . (Journal of Clinical Oncology, 10 April 2023, 41(11):1986-1991)
Subject
Language
English
ISSN
15277755
0732183X
0732183X